XML 25 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 26, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-37603    
Entity Registrant Name BIORESTORATIVE THERAPIES, INC.    
Entity Central Index Key 0001505497    
Entity Tax Identification Number 30-1341024    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 40 Marcus Drive    
Entity Address, Address Line Two Suite 1    
Entity Address, City or Town Melville    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 11747    
City Area Code (631)    
Local Phone Number 760-8100    
Title of 12(b) Security Common Stock $0.0001 par value    
Trading Symbol BRTX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 11,463,696
Entity Bankruptcy Proceedings, Reporting Current true    
Entity Common Stock, Shares Outstanding   7,504,780  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 688    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of BioRestorative Therapies, Inc. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name Marcum LLP    
Auditor Location Marlton, New Jersey